Generic AIDS drugs
Merck grants license to South African firm for a generic version of the AIDS drug Sustiva, but it is unclear whether efavirenz can be produced "at a price that is at or below the Merck no-profit price," Merck exec says during a conference sponsored by the American Enterprise Institute in Washington, D.C. May 12. FDA is working on a guidance on a streamlined approval process for generic AIDS treatments used in developing countries...
You may also be interested in...
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.